Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $53.29.

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group decreased their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. TD Cowen assumed coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday.

Halozyme Therapeutics Trading Down 0.9 %

Shares of Halozyme Therapeutics stock opened at $38.02 on Friday. The stock has a fifty day simple moving average of $39.44 and a 200 day simple moving average of $37.76. Halozyme Therapeutics has a 12-month low of $29.85 and a 12-month high of $45.00. The company has a market capitalization of $4.83 billion, a P/E ratio of 18.02, a price-to-earnings-growth ratio of 0.47 and a beta of 1.25. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. On average, sell-side analysts anticipate that Halozyme Therapeutics will post 3.33 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 30,000 shares of company stock worth $1,196,800. 2.70% of the stock is owned by company insiders.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HALO. TD Asset Management Inc lifted its holdings in Halozyme Therapeutics by 517.0% during the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after purchasing an additional 1,662,390 shares in the last quarter. Norges Bank purchased a new stake in Halozyme Therapeutics during the 4th quarter worth about $44,935,000. Epoch Investment Partners Inc. lifted its holdings in Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after purchasing an additional 831,199 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock worth $122,226,000 after purchasing an additional 595,220 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after purchasing an additional 563,989 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.